4.33

6.68% -0.31

After Hours: 4.33

Galectin Therapeutics Inc (GALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Galectin Therapeutics Inc stock is traded at $4.33, with a volume of 642.13K. It is down -6.68% in the last 24 hours and up +65.90% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Previous Close:

$4.64

Open:

$4.57

24h Volume:

642.13K

Relative Volume:

1.14

Market Cap:

$285.16M

Revenue:

Net Income/Loss:

$-26.25M

P/E Ratio:

-10.56

EPS:

-0.4099

Net Cash Flow:

$-20.05M

1W Performance:

+10.46%

1M Performance:

+65.90%

6M Performance:

+4.09%

1Y Performance:

+95.05%

1-Day Range:

$4.28

$4.6433

1-Week Range:

$3.8801

$5.19

52-Week Range:

$2.025

$7.13

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name

Galectin Therapeutics Inc

Sector

Healthcare (1092)

Industry

Biotechnology (615)

Phone

678-620-3186

Address

4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA

Employee

Twitter

@galectingalt

Next Earnings Date

2026-08-13

Latest SEC Filings

GALT's Discussions on Twitter

Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GALT Galectin Therapeutics Inc	4.33	305.58M	0	-26.25M	-20.05M	-0.4099
VRTX Vertex Pharmaceuticals Inc	498.01	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	624.72	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	909.50	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.67	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	187.51	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Resumed	H.C. Wainwright	Buy
Aug-13-20	Reiterated	H.C. Wainwright	Buy
Feb-13-19	Initiated	B. Riley FBR	Buy
Dec-07-17	Reiterated	H.C. Wainwright	Buy
Nov-28-17	Reiterated	H.C. Wainwright	Buy
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy
Sep-21-15	Initiated	H.C. Wainwright	Buy
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy
Jul-29-14	Reiterated	MLV & Co	Buy
Apr-02-14	Reiterated	MLV & Co	Buy
Feb-10-14	Reiterated	Aegis Capital	Buy
Jan-09-14	Reiterated	Aegis Capital	Buy
Dec-03-13	Initiated	MLV & Co	Buy
Aug-19-13	Reiterated	Aegis Capital	Buy

View All

Galectin Therapeutics Inc Stock (GALT) Latest News

Jun 30, 2026

Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Australia

Jun 30, 2026

Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia

Jun 30, 2026

Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com Canada

Jun 30, 2026

[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan

Jun 30, 2026

Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale - Stock Titan

Jun 30, 2026

Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga

Jun 30, 2026

Jun 29, 2026

Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares - Stock Titan

Jun 29, 2026

Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 28, 2026

GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN

Jun 28, 2026

Jun 27, 2026

GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN

Jun 27, 2026

Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK

Jun 27, 2026